- Home
- EXEL vs IEX Comparison
EXEL vs IEX Comparison
Compare EXEL & IEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | IEX |
|---|---|---|
| Founded | 1994 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 15.4B |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | EXEL | IEX |
|---|---|---|
| Price | $51.24 | $238.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | $46.50 | ★ $229.63 |
| AVG Volume (30 Days) | ★ 2.6M | 720.5K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.31% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | 1.60 | ★ 3.54 |
| Revenue | $452,477,000.00 | ★ $3,457,500,000.00 |
| Revenue This Year | $13.61 | $4.09 |
| Revenue Next Year | $13.13 | $4.36 |
| P/E Ratio | ★ $31.63 | $67.53 |
| Revenue Growth | N/A | ★ 5.77 |
| 52 Week Low | $33.76 | $158.19 |
| 52 Week High | $57.57 | $243.80 |
Technical Indicators
Market Signals| Indicator | EXEL | IEX |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 63.43 |
| Support Level | $50.80 | $216.54 |
| Resistance Level | $52.84 | $243.80 |
| Average True Range (ATR) | 1.95 | 5.86 |
| MACD | -0.61 | 0.57 |
| Stochastic Oscillator | 15.63 | 73.63 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. The company generated $3.5 billion in revenue in 2025.